Trial Profile
Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer in Brazil
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 25 May 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Eisai Inc
- 25 May 2018 New trial record